Neuronix

Company Overview

Snapshot

Founded in January 2008 by Jonathan Bentwich, Neuronix operated with 11–50 employees. The company raised $17.5M across three funding rounds. In March 2019, an FDA advisory panel rejected Neuronix's neuroAD system for Alzheimer's disease.

Business overview

Neuronix develops methods for treating Alzheimer's disease, focusing on long-term improvement in patient quality of life. Its core product, the neuroAD system, utilizes noninvasive cortical enhancer technology that combines magnetic stimulation with cognitive training, targeting specific brain regions affected by Alzheimer's. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving the healthcare market in the United States, Europe, and Israel.

Strategic signal

In March 2019, an FDA advisory panel rejected Neuronix's neuroAD system for Alzheimer's disease. This decision signaled a significant regulatory setback for the company, impacting its ability to commercialize its primary therapeutic device in the crucial US market and raising questions about its future operational viability.

Company Intelligence Q&A

What is Neuronix's primary focus?

Neuronix focuses on developing methods and technologies for modifying the course of treatment for Alzheimer's disease, aiming to improve patient quality of life.

What is the neuroAD system?

The neuroAD system is Neuronix's core product, based on noninvasive cortical enhancer technology that combines magnetic stimulation with cognitive training to target brain regions affected by Alzheimer's disease.

What was the outcome of the FDA advisory panel review for neuroAD?

In March 2019, an FDA advisory panel rejected Neuronix's neuroAD system for Alzheimer's disease, indicating a regulatory challenge for the company's market entry in the United States.

Has Neuronix conducted clinical studies for its technology?

Yes, Neuronix has completed a multi-center clinical study in the United States, which was intended to support a submission for US FDA clearance. Earlier studies performed at Beth Israel Deaconess Medical Center and other locations showed statistically significant clinical results.

What is the regulatory status of neuroAD in Europe?

The neuroAD therapy system is CE marked for commercial use in Europe for the treatment of Alzheimer's disease.